ProdromeNeuro™ Improves Cognition and Mobility in Cognitively Impaired Persons (C105)

Supplementation with ProdromeNeuro was observed to elevate DHA-plasmalogens in a dose-dependent manner and to improve cognition (p=1.8e-02) and mobility (p=2.9e-05) in persons diagnosed with mild to moderate dementia. 

To access the FREE seminars with full presentations and videos please visit Dr. Goodenowe’s resource site here. This is the article for seminar C105, Supplements (Series C).

ProdromeNeuro is a plasmalogen supplement designed to specifically elevate DHA plasmalogen levels. An escalating dose study was performed in 22 persons (11M/11F) diagnosed with various degrees of cognitive impairment to determine the optimal dose for elevating blood plasmalogen levels. 

Participants were clinically evaluated for cognition and mobility at baseline and after each month of supplement dosing. Cognitive status was evaluated using the Quick Dementia Rating System (QDRS), which was used to derive the participant’s Clinical Dementia Rating (CDR) score. Mobility was evaluated using the 30 second sit-stand test. Blood samples were collected for plasmalogen analyses at each clinical visit.  

The escalating dosing of ProdromeNeuro was performed as follows: 

Month 1 – 1ml/day (900mg/day – one bottle of ProdromeNeuro) 

Month 2 – 2ml/day (1800mg/day – two bottles of ProdromeNeuro) 

Month 3 – 2ml/day (1800mg/day – two bottles of ProdromeNeuro) 

Month 4 – 4ml/day (3600mg/day – four bottles of ProdromeNeuro) 

Month 5 – 0ml/day (0mg/day – zero bottles of ProdromeNeuro) 

Blood DHA-Plasmalogen levels were observed to be increased in all participants in a dose-dependent manner. After month 1 there was a 30% increase, after months 2 and 3 there was a 60% increase and after month 4 there was a 90% increase in the target DHA-plasmalogen levels. Persons with low baseline DHA-plasmalogen levels (quartiles 1 and 2) experienced a greater increase in blood DHA-plasmalogen levels (50%, 90%, and 120%, respectively).  When blood DHA-plasmalogen levels were expressed relative to an endogenous non-DHA phosphatidylethanolamine, the relative increase in the target DHA plasmalogen levels was more pronounced. 

The CDR score divides participants into questionable or very mild dementia (0.5), mild dementia (1), moderate dementia (2), or severe (3). Of the 22 participants, 14 had a baseline CDR of 0.5, four had a CDR of 1 and four had a CDR of 2. Of the four participants with moderate dementia (CDR 2), two improved to a CDR of 1 and one improved to a CDR of 0.5 and one participant progressed from a CDR of 2 to a 3. In the participant that declined significant negative non-trial related live events occurred in their life during the trial. Of the four participants with mild dementia (CDR 1), two improved to a CDR of 0.5 and two remained stable at CDR 1.  Of the 14 participants with questionable or very mild dementia (CDR 0.5), four improved to definite cognitive normal status (CDR 0), seven remained stable at CDR 0.5 and three declined. Of the persons who declined two had adverse life events that contributed to their decline. Of the eight persons with definite dementia (CDR 1 or 2), 5 (62.5%) showed clinical improvement and 7 (87.5%) remained stable or improved. Using a random prediction model based upon the observed decline rate, the observed improvement was statistically significant (p=1.8e-02). No relationship between baseline DHA-plasmalogen levels and clinical response was observed. Of the nine responders, five were in the low (Q1,Q2) group and four were in the high (Q3,Q4) group.  

The 30 second sit stand test is a common test used to evaluate core muscle strength and is strongly correlated with sarcopenia or muscle wasting. The test simply counts how many times a person can stand up and sit down in a 30 second period. A change from baseline of either +1 or -1 or 0 was considered stable. An increase of 2 or more was considered an improvement and a decrease of 2 or more was considered a decline. Three of the four participants with moderate dementia exhibited significant improvements in mobility (4 or 5 additional sit-stands) and one had a decline of 2 sit-stands. Of the participants with mild dementia, two exhibited improvement, one no change, and one declined. Of the 13 participants (one participant was unable to perform the test) with questionable or very mild dementia (CDR 0.5), 7 exhibited significant improvement, 4 were stable, and two declined. Using a random prediction model based upon the observed decline rate, the observed improvement was statistically significant (p=2.9e-05). 

ProdromeNeuro was well tolerated at all dosages and no adverse reactions were observed or reported. 

Dr. Goodenowe explains the trial design and clinical outcomes in C105 – ProdromeNeuro improves cognition and mobility in cognitively impaired persons. 

Share on facebook
Share on twitter
Share on linkedin
Your privacy is important to us.

To better protect your privacy, we provide this notice explaining our online information practices and the choices you can make about the way your information is collected and used. To make this notice easy to find, we make it available on our homepage and at every point where personally identifiable information may be requested.

Collection of Personal Information

When visiting, the IP address used to access the site will be logged along with the dates and times of access. This information is purely used to analyze trends, administer the site, track users’ movement and gather broad demographic information for internal use. Most important, any recorded IP addresses are not linked to personally identifiable information.

Links to Third-Party Websites
We have included links on this site for your use and reference. We are not responsible for the privacy policies on these websites. You should be aware that the privacy policies of these sites may differ from our own.
Our Use of Google Analytics
The Dr. Dayan Goodenowe website uses the Google Analytics tool to measure traffic on the site and traffic to the site via our online advertising. This includes using certain Advertising Features, which enable Google Analytics to collect data about users via Google advertising cookies and identifiers, in addition to anonymous data collected through the standard Google Analytics implementation. These Advertising Features, which may or may not be currently using, include:
  • Remarketing with Google Analytics. This allows us to display our ads to you as you search online for similar businesses.
  • Google Display Network Impression Reporting, which shows which of our ads users click on.
  • Google Analytics Demographics and Interest Reporting, which provides information about the age and gender of site users, along with the interests they express in their online travel and purchasing activities.
  • Integrated services that require Google Analytics to collect data via advertising cookies and identifiers.
We do not merge personally identifiable information with non-personally identifiable information collected through any Google advertising product or feature unless we have obtained robust notice of, and the user’s prior affirmative (i.e., opt-in) consent to, that merger. These Advertising Features, which may or may not be currently using, include:
Opt Out

There are several ways to opt out of interest-based advertising and/or all tracking related to Google Analytics and its advertising features.

You can opt out of interest-based ads by Google through Ads Settings. When you opt out, you’ll still see ads but they may not be related to factors such as your interests, previous visits to other websites, or demographic details. Obtain instructions here.

The Network Advertising Initiative offers a free tool that allows users to opt out from receiving interest-based ads from some or all NAI participating member companies that use cookies on your computer browser to collect data for interest-based advertising. Find information about it here.

Website visitors can totally block Google Analytics with the Google Analytics opt-out browser add-on (click to download). This add-on instructs the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) running on websites to prohibit their information from being used by Google Analytics. Using the Google Analytics opt-out plug-in will not prevent site owners from using other tools to measure site analytics. Learn more about about the opt-out and how to properly install the browser add-on here.

Changes to this Privacy

Statement The contents of this statement may be altered at any time, at our discretion.

If you have any questions regarding the privacy policy of then you may contact us at

terms of use
Welcome to our website. If you continue to browse and use this website, you are agreeing to comply with and be bound by the following terms and conditions of use, which together with our privacy policy govern’s relationship with you in relation to this website. If you disagree with any part of these terms and conditions, please do not use our website.

The term ‘’ or ‘us’ or ‘we’ refers to the owner of the website whose registered office is:

40880 County Center Drive
Suite R
Temecula, CA 92591, USA

The term ‘you’ refers to the user or viewer of our website.

The use of this website is subject to the following terms of use:

The content of the pages of this website is for your general information and use only. It is subject to change without notice.

Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.

Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable. It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.

This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the design, layout, look, appearance and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions.

All trademarks reproduced in this website, which are not the property of, or licensed to the operator, are acknowledged on the website.

Unauthorized use of this website may give rise to a claim for damages and/or be a criminal offence.

From time to time, this website may also include links to other websites. These links are provided for your convenience to provide further information. They do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s).

Your use of this website and any dispute arising out of such use of the website is subject to the laws of Canada and USA.

We use cookies to make this site as useful as possible. They are small text files we put in your browser to track usage of our site but they don’t tell us who you are. If you want to delete any cookies that are already on your computer, please refer to the instructions for your file management software to locate the file or directory that stores cookies.

This site is not a part of the Facebook website or Facebook Inc. Additionally, this site is not endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, Inc.